MeiraGTx Q2 net loss $34M; positive XLRP gene therapy data; extends cash runway to Q4 2024

MeiraGTx Holdings plc

2022-Q2 EPS reported -$1.46 revenue$16,392,000

Net loss of $34.0M ($0.76/share) vs $20.1M ($0.46) in Q2 2021; license revenue up to $10.8M.
Positive Phase 1/2 data for botaretigene sparoparvovec (AAV-RPGR) shows vision improvements in XLRP; Phase 3 Lumeos enrolling.
Secured up to $100M senior secured financing from Perceptive secured by manufacturing facilities; $75M received at close.
Cash and equivalents $72.1M at June 30 plus $15.9M Janssen receivable; cash runway to Q4 2024.
R&D expenses increased to $24.0M from $15.2M due to manufacturing and clinical costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.